Fuji Pharma Co., Ltd. (TYO:4554)
Japan · Delayed Price · Currency is JPY 2,339.00
+48.00 (2.10%)
May 29, 2026, 3:30 PM JST
Fuji Pharma Cash Flow Statement
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Net Income | 2,932 | 4,000 | 8,276 | 4,399 | 3,723 | 3,371 |
Depreciation & Amortization | 4,030 | 3,965 | 3,680 | 3,023 | 2,745 | 2,106 |
Loss (Gain) From Sale of Assets | - | 394 | - | 4 | 1 | 33 |
Loss (Gain) From Sale of Investments | 3,519 | - | -3,118 | - | - | -153 |
Other Operating Activities | -1,584 | -2,193 | -1,027 | -941 | -1,504 | -915 |
Change in Accounts Receivable | -252 | 525 | -1,997 | -3,705 | -549 | -174 |
Change in Inventory | -1,669 | -3,078 | 1,552 | -3,395 | -3,618 | -1,340 |
Change in Accounts Payable | -1,684 | 356 | -1,640 | -652 | 447 | 2,038 |
Change in Other Net Operating Assets | 2,438 | 1,832 | -1,575 | 3,184 | -1,903 | 1,027 |
Operating Cash Flow | 7,730 | 5,801 | 4,151 | 1,917 | -658 | 5,993 |
Operating Cash Flow Growth | 14.91% | 39.75% | 116.54% | - | - | 3.86% |
Capital Expenditures | -2,222 | -1,981 | -2,778 | -3,327 | -5,097 | -3,789 |
Sale of Property, Plant & Equipment | 5 | 2 | 2 | 10 | 1,383 | 1,673 |
Sale (Purchase) of Intangibles | -1,130 | -1,873 | -1,594 | -570 | -7,326 | -107 |
Investment in Securities | - | - | 5,356 | - | - | 189 |
Other Investing Activities | -85 | -367 | -2,644 | -1,353 | -231 | -311 |
Investing Cash Flow | -3,432 | -4,219 | -1,658 | -5,240 | -11,271 | -2,345 |
Short-Term Debt Issued | - | - | 4,000 | 3,000 | 1,300 | 6,000 |
Long-Term Debt Issued | - | 9,987 | - | 2,985 | 7,300 | 1,000 |
Total Debt Issued | 1 | 9,987 | 4,000 | 5,985 | 8,600 | 7,000 |
Long-Term Debt Repaid | - | -7,749 | -5,210 | -2,740 | -2,140 | -1,756 |
Total Debt Repaid | -2,181 | -7,749 | -5,210 | -2,740 | -2,140 | -1,756 |
Net Debt Issued (Repaid) | -2,180 | 2,238 | -1,210 | 3,245 | 6,460 | 5,244 |
Issuance of Common Stock | 3,339 | 210 | 55 | - | - | 11 |
Repurchase of Common Stock | - | - | - | - | - | -9,405 |
Common Dividends Paid | -1,113 | -1,036 | -972 | -899 | -729 | -807 |
Other Financing Activities | -454 | -458 | 1,692 | -431 | -637 | -478 |
Financing Cash Flow | -408 | 954 | -435 | 1,915 | 5,094 | -5,435 |
Foreign Exchange Rate Adjustments | 301 | 123 | 202 | 185 | 183 | -55 |
Miscellaneous Cash Flow Adjustments | 1 | 1 | - | 2 | -1 | - |
Net Cash Flow | 4,192 | 2,660 | 2,260 | -1,221 | -6,653 | -1,842 |
Free Cash Flow | 5,508 | 3,820 | 1,373 | -1,410 | -5,755 | 2,204 |
Free Cash Flow Growth | 6.58% | 178.22% | - | - | - | -36.08% |
Free Cash Flow Margin | 9.61% | 7.39% | 2.98% | -3.45% | -16.25% | 6.48% |
Free Cash Flow Per Share | 223.71 | 156.54 | 56.48 | -58.02 | -236.90 | 82.03 |
Cash Interest Paid | 374 | 327 | 194 | 104 | 82 | 59 |
Cash Income Tax Paid | 1,588 | 2,197 | 1,026 | 946 | 1,498 | 911 |
Levered Free Cash Flow | 4,655 | 535.5 | 599.13 | -4,258 | -11,724 | 1,392 |
Unlevered Free Cash Flow | 4,892 | 741.75 | 721.63 | -4,182 | -11,676 | 1,425 |
Change in Working Capital | -1,167 | -365 | -3,660 | -4,568 | -5,623 | 1,551 |